(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 December 2008 (11.12.2008)

PCT

(10) International Publication Number
WO 2008/150118 A3

(51) International Patent Classification:
C07D 403/12 (2006.01)

(21) International Application Number:
PCT/KR2008/003162

(22) International Filing Date: 5 June 2008 (05.06.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10-2007-0054997 5 June 2007 (05.06.2007) KR

(71) Applicant *(for all designated States except US)*: **HANMI PHARM. CO., LTD.** [KR/KR]; #893-5, Hajeo-ri, Paltan-myeon, Hwaseong-si, Gyeonggi-do 445-910 (KR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **LEE, Kwang-Ok** [KR/KR]; LG Xi Apt. 912-401, Sanghyeon 2-dong, Suji-gu, Yongin-si, Gyeonggi-do 448-529 (KR). **CHA, Mi Young** [KR/KR]; Halla Apt. 306-1102, Cheong-solmaeul, Geumgok-dongBundang-gu, Seongnam-si, Gyeonggi-do 463-725 (KR). **KIM, Mi Ra** [KR/KR]; 102-ho, #7-31, Yangjae-dong, Seocho-gu, Seoul 137-130 (KR). **JUNG, Young Hee** [KR/KR]; #32-19, Yeok-chon-dong, Eunpyeong-gu, Seoul 122-898 (KR). **LEE, Chang Gon** [KR/KR]; Laonyu Apt. 110-1303, Dun-deok-dong, Yeosu-si, Jeollanam-do 550-250 (KR). **KIM, Se Young** [KR/KR]; Jaeil Apt. Ga-301, Hadae-won-dong, Jungwon-gu, Seongnam-si, Gyeonggi-do 462-110 (KR). **BANG, Keukchan** [KR/KR]; Mansu Jugong Apt. 1104-1203, Mansu 2-dong, Namdong-gu, Incheon-si 405-744 (KR). **PARK, Bum Woo** [KR/KR]; Keangnam Honorsville 108-2003, Boramae, Singil 6-dong, Youngdeungpo-gu, Seoul 150-781 (KR). **CHOI, Bo Im** [KR/KR]; Daesang Villa B-302, Ye-lim-ri, Sangnam-myeon, Milyang-si, Gyeongsangnamdo 627-914 (KR). **CHAE, Yun Jung** [KR/KR]; Dong-won Apt. 105-1902, Nakmin-dong, Dongrae-gu, Busan 607-754 (KR). **KO, Mi Young** [KR/KR]; 203-ho, 17/1, #504-7, Gokbanjeong-dong, Gwonseon-gu, Suwon-si, Gyeonggi-do 441-400 (KR). **KIM, Han Kyong** [KR/KR]; #180-22, Jaeil-ri, Yangji-myeon, Cheoin-gu, Yongin-si, Gyeonggi-do 449-825 (KR). **AHN, Young-Gil** [KR/KR]; Life Apt. 101-1901, Sangnokmaeul, Jeongja-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463-785 (KR). **KIM, Maeng Sup** [KR/KR]; Dunchon Jugong Apt. 301-203, Dunchon-dong, Gangdong-gu, Seoul 134-060 (KR). **LEE, Gwan Sun** [KR/KR]; Woochang Apt. 3-404, Okeum-dong, Songpa-gu, Seoul 138-739 (KR).

(74) Agents: **JANG, Seongku** et al.; 19th Fl., Trust Tower, #275-7, Yangjae-dong, Seocho-ku, Seoul 137-130 (KR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
29 January 2009

(54) Title: NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS

(57) Abstract: The present invention provides a novel amide derivative and a pharmaceutically acceptable salt thereof which selectively and effectively inhibits the growth of cancer cells induced by the overexpression of an epidermal growth factor receptor and also prevents the development of drug resistance caused by the mutation of EGFR tyrosine kinase, and a pharmaceutical composition comprising same as an active ingredient.

WO 2008/150118 A3